Skip to main content

Advertisement

Table 1 Patient demographics and baseline disease characteristics of the ITT population [10]

From: Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis

Characteristic Placebo (n = 500) Peginterferon beta-1a 125 μg every 4 weeks Peginterferon beta-1a 125 μg every 2 weeks
(n = 500) (n = 512)
Age, years 36.3 (9.74) 36.4 (9.87) 36.9 (9.79)
Gender, % female 72 70 71
Time since first MS symptoms, years 6.3 (6.28) 6.5 (6.07) 6.9 (6.61)
Relapses within the previous 12 months 1.6 (0.67) 1.5 (0.62) 1.6 (0.67)
EDSS Score 2.44 (1.18) 2.48 (1.24) 2.47 (1.26)
Number who took any prior MS medicationa, n (%) 86 (17) 85 (17) 89 (17)
No Gd+ lesions, n (%) 296 (59) 297 (59) 334 (65)
Number of T2 lesions 50.6 (35.7) 51.4 (36.0) 48.7 (36.8)
Number of T1 hypointense lesions 28.1 (29.2) 29.6 (30.8) 27.8 (28.1)
Number of Gd+ lesions 1.6 (3.81) 1.8 (5.38) 1.2 (3.44)
Volume of T2 lesions, cm3 10.1 (11.9) 11.3 (13.2) 9.8 (11.6)
Volume of T1 hypointense lesions, cm3 3.1 (4.80) 3.1 (4.76) 3.0 (4.50)
  1. MRI results are reported for a slightly smaller number of patients compared with the ITT population (due to the availability of MRI scans to analyze). Data are presented as mean (standard deviation), unless otherwise stated. aInterferon beta-1a, interferon beta-1b, or glatiramer acetate.
  2. EDSS = Expanded Disability Status Scale; Gd+ = gadolinium-enhancing; MS = multiple sclerosis.